

**UNITED STATES INTERNATIONAL TRADE COMMISSION**  
**Washington, D.C.**

**In the Matter of**

**CERTAIN PRODUCTS CONTAINING  
TIRZEPATIDE AND PRODUCTS  
PURPORTING TO CONTAIN  
TIRZEPATIDE**

**Investigation No. 337-TA-1377**

**NOTICE OF A COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL  
DETERMINATION FINDING A RESPONDENT IN DEFAULT**

**AGENCY:** U.S. International Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the U.S. International Trade Commission (“Commission”) has determined not to review an initial determination (“ID”) (Order No. 23) of the presiding administrative law judge (“ALJ”) finding respondent Fibonacci Sequence LLC d/b/a GenX Peptides (“GenX”) in default.

**FOR FURTHER INFORMATION CONTACT:** Edward S. Jou, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street, S.W., Washington, D.C. 20436, telephone (202) 205-3316. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email [EDIS3Help@usitc.gov](mailto:EDIS3Help@usitc.gov). General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on November 27, 2023, based upon a complaint filed on behalf of Eli Lilly and Company of Indianapolis, Indiana. 88 FR 82914-15 (Nov. 27, 2023). The complaint, as supplemented, alleges violations of section 337 based upon the importation into the United States and the sale of certain products containing tirzepatide or purporting to contain tirzepatide by reason of false designation of source and false and misleading advertising, the threat or effect of which is to destroy or substantially injure an industry in the United States, and based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain products containing tirzepatide or purporting to contain tirzepatide by reason of infringement of U.S. Trademark No. 6,809,369. *Id.* The complaint also alleges that a domestic industry exists pursuant to subsection (a)(2) of section 337. *Id.*

The Commission's notice of investigation named as respondents Arctic Peptides LLC of Akeny, Iowa; Audrey Beauty Co. of Hong Kong, China; Biolabshop Limited of Lancaster, United Kingdom; Mew Mews Company Limited of Hong Kong, China; Strate Labs LLC of Spring, Texas; Steroide Kaufen of Bialystok, Poland; Super Human Store of Barcelona, Spain; Supopeptide of Cedar Grove, New Jersey; Triggered Supplements LLC of Clearwater, Florida; Unewlife of Cedar Grove, New Jersey; and Xiamen Austronext Trading Co., Ltd. of Fujian, China. *Id.* at 82915. The Office of Unfair Import Investigations is also named as a party in this investigation. *Id.*

Respondents Unewlife, Supopeptide, and Steroide Kaufen were terminated pursuant to withdrawal of the complaint. *See* Order No. 8 (Mar. 7, 2024), *unreviewed by* Comm'n Notice (Mar. 21, 2024). Respondents Arctic Peptides LLC; Audrey Beauty Co., Ltd.; Biolabshop Limited; Mew Mews Co. Ltd.; Strate Labs LLC; Super Human Store; Triggered Supplements LLC (d/b/a The Triggered Brand); and Xiamen Austronext Trading Co., Ltd. (d/b/a AustroPeptide) have been found in default. *See* Order No. 13 (Apr. 22, 2024), *unreviewed by* Comm'n Notice (May 15, 2024).

On May 21, 2024, the complaint and notice of investigation were amended to add two respondents: GenX of Houston, Texas; and Paradigm Peptides of Michigan City, Indiana. Order No. 12 (Apr. 22, 2024), *unreviewed by* Comm'n Notice, 89 FR 46159-60 (May 28, 2024). On June 13, 2024, the complaint and notice of investigation were further amended to add an additional respondent, Total Compounding Pharmaceuticals of Australia. Order No. 16 (May 17, 2024), *unreviewed by* Comm'n Notice, 89 FR 51549-50 (June 18, 2024).

On August 7, 2024, the ALJ issued an order (Order No. 22) directing respondent GenX to show cause why it should not be found in default by August 23, 2024. The ALJ found that GenX had received notice of the amended complaint and notice of investigation by express delivery to an address in Texas. *See* Order No. 22 at 4 (Aug. 7, 2024). The ALJ found that after receiving such notice, GenX did not respond, did not enter an appearance, and did not demonstrate any intent to participate in the investigation. *Id.* at 7.

On August 27, 2024, the ALJ issued the subject ID (Order No. 23) finding GenX in default because it did not respond to the show cause order. No petitions for review of the ID were filed.

The Commission has determined not to review the subject ID, and accordingly, GenX has been found in default.

The Commission vote for this determination took place on September 26, 2024.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

A handwritten signature in black ink, appearing to read 'Lisa R. Barton', enclosed within a large, stylized circular flourish.

Lisa R. Barton  
Secretary to the Commission

Issued: September 26, 2024